- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novartis AG (NOVNz)"Novartis AG stock price live, this page displays SIX NOVN stock exchange data. View the NOVN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Novartis AG real time stock price chart below.
What Is the Novartis AG Stock Price Today?
The Novartis AG stock price today is 88.720.
What Is the Stock Symbol for Novartis AG?
The stock symbol for Novartis AG is ""NOVN.""
What Stock Exchange Does Novartis AG Trade On?
Novartis AG is listed and trades on the Switzerland stock exchange.
Is Novartis AG a Good Stock to Buy?
Determining whether Novartis AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NOVN quote. (ISIN: CH0012005267)"
What Is the Novartis AG Stock Price Today?
The Novartis AG stock price today is 88.720.
What Is the Stock Symbol for Novartis AG?
The stock symbol for Novartis AG is ""NOVN.""
What Stock Exchange Does Novartis AG Trade On?
Novartis AG is listed and trades on the Switzerland stock exchange.
Is Novartis AG a Good Stock to Buy?
Determining whether Novartis AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NOVN quote. (ISIN: CH0012005267)"
88.720
-0.630(-0.71%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
88.720
89.780
52 wk Range
83.660
102.720
NOVNz Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
88.72089.780
52 wk Range
83.660102.720
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.69%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(3.69%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NOVNz Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
115.730
Upside
+30.385%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 28 consecutive years
- Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Novartis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Novartis AG Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Compare NOVNz to Peers and Sector
Metrics to compare | NOVNz | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNOVNzPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.3x | 17.3x | −0.6x | |
PEG Ratio | 0.13 | −0.35 | 0.00 | |
Price/Book | 4.7x | 1.8x | 2.6x | |
Price / LTM Sales | 4.1x | 2.3x | 3.2x | |
Upside (Analyst Target) | - | 17.0% | 46.2% | |
Fair Value Upside | Unlock | 19.0% | 7.0% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.65
Dividend Yield
3.69%
Industry Median 1.27%
Annualized payout
3.3000
Paid annually
5-Years Growth
-
Growth Streak
People Also Watch
FAQ
What Is the Novartis (NOVNz) Stock Price Today?
The Novartis stock price today is 88.72
What Stock Exchange Does Novartis Trade On?
Novartis is listed and trades on the BATS Europe stock exchange.
What Is the Stock Symbol for Novartis?
The stock symbol for Novartis is "NOVNz."
Does Novartis Pay Dividends? What’s The Current Dividend Yield?
The Novartis AG dividend yield is 3.69%.
What Is the Novartis Market Cap?
As of today, Novartis market cap is 177.78B.
What is Novartis Earnings Per Share?
The Novartis EPS is 8.65.
From a Technical Analysis Perspective, Is NOVNz a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.